Logo image of MAZE

MAZE THERAPEUTICS INC (MAZE) Stock Fundamental Analysis

USA - NASDAQ:MAZE - US5787841007 - Common Stock

27.11 USD
+0.61 (+2.3%)
Last: 10/3/2025, 8:00:01 PM
27.11 USD
0 (0%)
After Hours: 10/3/2025, 8:00:01 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to MAZE. MAZE was compared to 196 industry peers in the Pharmaceuticals industry. MAZE has an excellent financial health rating, but there are some minor concerns on its profitability. MAZE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year MAZE was profitable.
In the past year MAZE has reported a negative cash flow from operations.
MAZE Yearly Net Income VS EBIT VS OCF VS FCFMAZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

With an excellent Return On Assets value of 1.12%, MAZE belongs to the best of the industry, outperforming 81.63% of the companies in the same industry.
MAZE's Return On Equity of 1.30% is amongst the best of the industry. MAZE outperforms 81.12% of its industry peers.
The Return On Invested Capital of MAZE (16.04%) is better than 93.88% of its industry peers.
Industry RankSector Rank
ROA 1.12%
ROE 1.3%
ROIC 16.04%
ROA(3y)-71.89%
ROA(5y)N/A
ROE(3y)-370.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MAZE Yearly ROA, ROE, ROICMAZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

MAZE has a better Profit Margin (2.03%) than 80.61% of its industry peers.
MAZE's Operating Margin of 34.38% is amongst the best of the industry. MAZE outperforms 95.92% of its industry peers.
Industry RankSector Rank
OM 34.38%
PM (TTM) 2.03%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MAZE Yearly Profit, Operating, Gross MarginsMAZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MAZE is creating some value.
MAZE has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for MAZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MAZE Yearly Shares OutstandingMAZE Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
MAZE Yearly Total Debt VS Total AssetsMAZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

MAZE has an Altman-Z score of 17.10. This indicates that MAZE is financially healthy and has little risk of bankruptcy at the moment.
MAZE has a better Altman-Z score (17.10) than 88.27% of its industry peers.
MAZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.1
ROIC/WACC1.63
WACC9.85%
MAZE Yearly LT Debt VS Equity VS FCFMAZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 13.63 indicates that MAZE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 13.63, MAZE belongs to the top of the industry, outperforming 87.24% of the companies in the same industry.
MAZE has a Quick Ratio of 13.63. This indicates that MAZE is financially healthy and has no problem in meeting its short term obligations.
MAZE has a better Quick ratio (13.63) than 87.24% of its industry peers.
Industry RankSector Rank
Current Ratio 13.63
Quick Ratio 13.63
MAZE Yearly Current Assets VS Current LiabilitesMAZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 103.39% over the past year.
EPS 1Y (TTM)103.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-413.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, MAZE will show a very strong growth in Earnings Per Share. The EPS will grow by 23.36% on average per year.
The Revenue is expected to decrease by -74.51% on average over the next years. This is quite bad
EPS Next Y86.47%
EPS Next 2Y37.03%
EPS Next 3Y23.36%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-74.51%
Revenue Next 5YN/A

3.3 Evolution

MAZE Yearly Revenue VS EstimatesMAZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2027 50M 100M 150M
MAZE Yearly EPS VS EstimatesMAZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -5 -10 -15 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 338.88, the valuation of MAZE can be described as expensive.
76.53% of the companies in the same industry are more expensive than MAZE, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.86. MAZE is valued rather expensively when compared to this.
MAZE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 338.88
Fwd PE N/A
MAZE Price Earnings VS Forward Price EarningsMAZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MAZE indicates a rather cheap valuation: MAZE is cheaper than 82.65% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 14.86
MAZE Per share dataMAZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MAZE's earnings are expected to grow with 23.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.92
PEG (5Y)N/A
EPS Next 2Y37.03%
EPS Next 3Y23.36%

More info and screens

0

5. Dividend

5.1 Amount

MAZE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAZE THERAPEUTICS INC

NASDAQ:MAZE (10/3/2025, 8:00:01 PM)

After market: 27.11 0 (0%)

27.11

+0.61 (+2.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)N/A N/A
Inst Owners71.51%
Inst Owner Change-7.34%
Ins Owners2.13%
Ins Owner Change-0.31%
Market Cap1.19B
Analysts86.67
Price Target38.76 (42.97%)
Short Float %4.56%
Short Ratio3.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.93%
Min EPS beat(2)-49.66%
Max EPS beat(2)11.81%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)55.1%
PT rev (3m)61.7%
EPS NQ rev (1m)7.43%
EPS NQ rev (3m)20.48%
EPS NY rev (1m)12.7%
EPS NY rev (3m)13.79%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE 338.88
Fwd PE N/A
P/S 7.1
P/FCF N/A
P/OCF N/A
P/B 4.53
P/tB 4.53
EV/EBITDA 14.86
EPS(TTM)0.08
EY0.3%
EPS(NY)-2.98
Fwd EYN/A
FCF(TTM)-2.43
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS3.82
BVpS5.98
TBVpS5.98
PEG (NY)3.92
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.12%
ROE 1.3%
ROCE 20.3%
ROIC 16.04%
ROICexc 238.46%
ROICexgc 238.46%
OM 34.38%
PM (TTM) 2.03%
GM N/A
FCFM N/A
ROA(3y)-71.89%
ROA(5y)N/A
ROE(3y)-370.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 49.54%
Cap/Sales 0.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.63
Quick Ratio 13.63
Altman-Z 17.1
F-Score6
WACC9.85%
ROIC/WACC1.63
Cap/Depr(3y)32.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)103.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-413.49%
EPS Next Y86.47%
EPS Next 2Y37.03%
EPS Next 3Y23.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-74.51%
Revenue Next 5YN/A
EBIT growth 1Y158.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-704.89%
EBIT Next 3Y-112.39%
EBIT Next 5YN/A
FCF growth 1Y185.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y187.48%
OCF growth 3YN/A
OCF growth 5YN/A